kabs.com Revenue $27.2 Million KABS Laboratories is a Canadian pharmaceutical CDMO founded in 1997 in Saint-Hubert, Quebec by Dr. Jean-Simon Blais and Dr. Gérard Akinocho, with 150+ specialists serving clients in 28 countries. It is a WHO prequalified Quality Control Laboratory audited by Health Canada, USFDA and EU QPs, offering aseptic manufacturing from 100 to 100,000 vials per batch. In 2021 it received CAD 54.2 million from Canada's Strategic Innovation Fund to expand fill-and-finish to 30 million vials per year and build a bioprocessing plant for monoclonal antibodies. Through joint venture MendeliKABS it developed MDK-Nitisinone, an orphan drug for tyrosinemia type 1, priced 10 times lower than the Swedish competitor and approved in Europe, UK, Brazil, China and Algeria. The company also runs an African quality control office in Benin.